House and Senate Committees Pass FY2016 Appropriations Bills Increasing Funding for NIH and NCI
Funding has NOT kept pace with the translation of bench research- basic scientific inquiry into thoughtful and fruitful possible clinical trials. These actions are a glimmer of hope and the first thing the new President of ASCO went after a few weeks ago in her testimony to Congress. The Silver Tsunami effect is real- as we age , there will be more cancers and more therapies of more expense. We may soon be on course for Cancer, not Cardiovascular and heart disease , as our number one killer. This IS your problem as 40% of you will be touched by cancer personally or in a loved one and the enrollment of patients in clinical trials is NOT keeping pace with the discoveries from basic research needing clinical trials to answer new questions and improve present therapies Dr. Ryan
This week, the U.S. Senate and House of Representatives Appropriations Committees each approved spending bills for fiscal year 2016 that would provide increased funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
The Senate appropriations bill would provide $32 billion to NIH, an increase of $1.9 billion above the fiscal year 2015 budget. Of the $32 billion, $5.2 billion would go to NCI, increasing the Institute’s budget by five percent from 2015. ASCO supports the Senate’s bill, which is in line with the minimum funding for NIH and NCI requested by the Society for fiscal year 2016. If enacted, this would be the largest annual increase in funding for NIH and NCI since 2003.
The House appropriations bill would also increase funding for NIH and NCI, providing $31.2 billion for NIH and $5.08 billion to NCI. ASCO was disappointed to see that both bills include cuts to funding for Agency for Healthcare Research and Quality’s (AHRQ), the House Appropriations Committee bill would completely eliminate AHRQ and while the bill passed by the Senate include a thirty-five percent cut to the agency.